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Factors contributing for improved graft survival in recipients of kidney
transplants. We analyzed the survival results of 300 consecutive kidney
transplants (TX5) performed at Hennepin County Medical Center,
Minneapolis, Minnesota, between March 1965 and April 1980. The graft
survival results were compared between three sequential time periods,
each comprising 100 renal TXs. The proportion of live donor TXs
decreased from 27% in period Ito 16% in period 2 and 5% in period 3,
while the number of older patients, diabetic and multiple TX patients
increased steadily. A comprehensive patient care scheme utilizing
clinical protocols was developed in period 2 and carried out effectively
in period 3. The Cox multivanate regression models used in this
analysis allowed us to assess the influence of each variable on the graft
survival results, while the effects of all others were held constant.
Among the nondiabetic patients who received antilymphocyte globulin,
the I and 5 year graft survival rates were 59.7 and 38.8% in period I,
85.3 and 74.3% in period 2, 90.4 and 83.1% in period 3 (periods 1 versus
2: P = 0.008, periods 1 versus 3: P < 0.0001). This improvement in graft
survival was independent of the effects of the following variables, that
is, the recipient's age, donor source, prior dialysis, co-existing medical
problems, splenectomy, previous TXs, blood transfusions, cytotoxic
antibodies, cold ischemia time, HLA mismatches, and post-TX acute
tubular necrosis. Our observations indicate that reduced immunosup-
pression, frequent use of biopsy specimens and comprehensive patient
care, played an important role in minimizing the loss of renal trans-
plants in the later time periods and contributed indirectly for the
improved graft survival results at our institution.
Facteurs contribuant pour l'amélioration de survie du greffon chez les
receveurs de transplant de rein. Nous avons analyse les données
concernant Ia survie des greffes de 300 transplantes rénaux consécutifs
(TXs) faites au Hennepin County Medical Center, Minneapolis, Minne-
sota, entre Mars 1965 et Avril 1980. Les résultats ont été compares
entre trois périodes de temps successives, chacune comprenant 100
TXs rénales. La proportion de donneur vivants de TXs a diminué de
27% dans Ia période I a 16% dans Ia période 2 eta 5% dans Ia période 3,
tandis que le nombre de patients plus âgés, de patients diabetiques, ou
de TXs répétées a augmente continuellement. Un schema de soin
rationnel aux malades utilisant des protocoles cliniques a été développé
pendant Ia periode 2 et utilisé effectivement dans Ia période 3. Les
modèles de regression multi-factorielle de Cox utilisés paurcette ana-
lyse ont permis de préciser l'influence de chaque variable sur les
rCsultats de Ia survie de la greffe, alors que les effets des autres étaient
maintenus constants. Parmi les patients non diabétiques qui ont recu du
serum anti-lymphocytaire, les taux de survie de Ia greffe a 1 et 5 ans
étaient de 59,7 et 38,8% dans Ia période 1, 85,3 et 74,3% dans Ia periode
2, 90,4 et 83,1% dans Ia période 3 (pénode 1 contre période 2: P =
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0.008, période I contre periode 3: P < 0.0001). Cette amelioration de Ia
survie du transplant était indépendante des effets des variables sui-
vantes: age du receveur, origine du donneur, dialyse antérieure, prob-
lémes médicaux associés, splénectomie, TXs antérieures, transfusions
sanguines, anticorps cytoxiques, durée d'ischémie froide, incompatibi-
lité HLA, et insuffisance rénale aigue post TX. Nos observations
indiquent qu'une diminution de l'immunosuppression, une utilisation
fréquente de specimens biopsiques et un soin rationnel aux malades ont
joué un role important pour minimiser Ia perte de transplants rénaux
dans Ia dernière période de temps, et ont contribué indirectement a
l'amélioration des résultats de la survie du greffon dans notre institut.
Since the early 1960s renal transplantation has become an
acceptable mode of therapy for patients with endstage renal
failure [1]. Much progress has been made since then because of
innovative discoveries such as tissue typing [2], organ preserva-
tion and transport [3, 4], cytotoxic antibody screening and
crossmatching [5, 6], and the beneficial effect of pretransplant
blood transfusions on the survival of cadaveric renal allografts
[7, 8]. Besides the clinical experience acquired over the years,
factors such as splenectomy [9, 10], administration of antilym-
phocyte globulin (ALG) [11—13], and reduction in the dose of
corticosteroids [14} were all reported to be beneficial in improv-
ing the outcome of clinical transplantation.
Vincenti et al [14] and Tilney et a! [15] recently reported a
significant improvement in the survival of patients following
renal transplantation. During the same period, however, there
was a modest increase in graft survival in recipients of related
donor transplants, but the graft survival in cadaveric transplant
recipients remained low. Approximately half of these patients
suffered graft loss within a year following transplantation.
From the inception of the transplant program at Hennepin
County Medical Center (HCMC), Minneapolis, Minnesota, the
primary emphasis was laid on cadaveric renal transplantation.
During the past 15 years, several of the techniques and treat-
ment methods described above have been adapted at our
institution. In this study, we used the Cox exploratory multivar-
iate regression analysis [16] which allowed us (1) to evaluate the
significance of each variable, from a group of selected variables
known to affect the graft survival, (2) to compare the results
between three sequential time periods, each period comprising
100 consecutive kidney transplants. The results indicated a
progressive improvement in graft survival rate in recipients of
renal transplants at our institution, The policies and procedures
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Fig. 1. Renal transplants performed at
Hennepin County Medical Center by year and
donor source.
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Table 1. Policies and procedures in different time periods
Policies and procedures
Period 1
1965 to 1974
Period 2
1974 to 1977
Period 3
1977 to 1980
Administrative changes Surgical transplant
unit only
Establishment of a medical TX
unit
Better organization of TX clinic
Comprehensive patient care
Development of clinical protocols
Protocols effectively
carried out
Tissue typing and crossmatch tech-
niques Primitive Improved Improved
Diagnosis of rejection Clinical grounds Clinical and histological Clinical and histological
Allograft biopsies done 10 50 65
Treatment of rejections
Total dose of i.v. Solumedrol, grams
Total dose of Prednisone over the
next 4 weeks, mg
5.0 to 7.0
1470
4.5 to 5.0
1260
3.5 to 3.75
1050
Maintenance dose of Prednisone I year
following TX, mg 30 to 15/day 15/day to 1974
1 5/QOD (75 to 77)
15 QOD
Abbreviation: TX, transplant.
followed in different time periods and their impact on the renal
allograft survival form the basis of this report.
Methods
Between March 15, 1965, and April 24, 1980, 321 renal
transplants were performed at FICMC. Twenty-one transplants
performed between 1965 and 1972 were excluded from this
study because of inadequate information. The remaining 300
kidney transplants and the years in which they were performed
are shown diagrammatically in Figure 1. Of these, 253 were
primary transplants, 44 were second transplants, and 3 were
third transplants. Forty-one patients who received two renal
transplants and three patients who received three allografts
each were counted as new patients with each subsequent
transplant. The end points for the study were (1) the date of
patient death, (2) the date of reinstitution of regular dialysis,
and (3) the date when the data was collected for statistical
analysis, that is, May 6, 1981. A patient's death from any cause
was considered as an end point. Regular dialysis was reinstitut-
ed when the creatinine clearance decreased to 15 mI/mm, or
less, without a reversible cause. All patients were exposed to
65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80
Time, years
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the risk of transplantation for a minimum of I year before the
graft survival results were analyzed.
Time periods. The clinical results were evaluated in three
sequential time periods. Period 1 comprised the experience with
100 renal transplants performed between March 15, 1965, and
June 7, 1974. Period 2 constituted the time frame between June
27, 1974, and December 11, 1977. Period 3 was the interval
between December 19, 1977, and April 24, 1980.
At the onset of the second period, the transplant program was
reorganized into a medical/surgical unit with designated respon-
sibilities for individual services (Table 1). The medical team was
primarily responsible for pretransplant evaluation, post-trans-
plant follow-up and in-hospital management of patients when
they were admitted with a medical complication. The surgical
team was responsible for the harvesting, the preservation, and
the transport of cadaver kidneys, performing the surgical proce-
dures in the pre- and post-transplant period and in-hospital
management of patients when they were admitted with a
surgical complication or a critical illness. Irrespective of the
patient's admission to the medical or surgical ward, both teams
made combined rounds. The patient-related problems were also
discussed at the weekly transplant meetings attended both by
the medical and surgical services. A comprehensive scheme
utilizing clinical protocols was developed at this time, with the
objective of providing total patient care during the post-trans-
plant period.
Post-transplant follow-up care. After transplantation, pa-
tients were followed at regular intervals in the transplant clinic.
The clinic was staffed by four nurses and two secretaries. They
were responsible for coordinating the patient care activities and
for acquiring the clinical and laboratory data on all patients
followed through the clinic. Each nurse had approximately 30
pretransplant patients and 50 post-transplant patients assigned
on an alphabetical basis. The nurses followed the patients
closely during the pre- and post-transplant period, including the
time when they were hospitalized for a medical or surgical
complication. They frequently communicated with paramedical
support personnel such as the dietician, social worker, financial
counselor, clinical psychologist, and the community physicians
who were involved in the follow-up care of our transplant
patients. All of the events related to patient care were docu-
mented chronologically in the medical record and the patient's
flow chart. The routine clinic visits were gradually reduced
from once a day during the third week to once a month for a
year after transplantation. The clinical and laboratory data on
all patients were obtained and reviewed at frequent intervals,
during the entire post-transplant period. All patients with
functioning renal transplants were seen in the clinic once a year
for a complete annual evaluation.
Patients living outside the metropolitan area were sent back
to their home towns, approximately 2 months after transplanta-
tion. After the initial 2 weeks of hospitalization, they were
observed in the clinic as outpatients. This policy has helped us
in handling their immediate post-transplant complications. Pa-
tients were returned to the care of their home town physicians
only when their clinical status was normal and the renal
function was stable. At this time a copy of the flow chart
(containing pertinent clinical and laboratory data), the problem
list, and the schedule of follow-up visits (indicating the frequen-
cy and the type of data required at each visit), was sent to the
local physician. The physicians or the patients themselves have
regularly forwarded the clinical and laboratory data to our
facility, which were entered in the respective flow charts. Each
patient's data were routinely reviewed once a month and
appropriate steps were taken whenever significant abnormali-
ties were discovered.
All patients were encouraged to contact the clinic or the
transplant physician "on call" for medical, surgical, or psycho-
social problems. However, in case of medical emergencies,
patients living outside the metropolitan area were advised to
consult their local physician. All telephone calls from the
transplant patients during the nights, weekends and holidays
were handled by three of us who were familiar with the patient's
problems on a continual basis. The rotating medical and surgi-
cal residents participated in the care of transplant patients only
under the direct supervision of the three staff physicians.
Excellent communication was established between us and the
community physicians, so that everyone involved was aware of
the problems in individual patients.
Immunological studies. The tissue typing and crossmatching
tests were performed at the immunology laboratory of the
University of Minnesota. These tests were either not available
or primitive in period 1. However, the techniques have im-
proved considerably during the later time periods [61. Presently,
the crossmatching is done by using donor lymphocytes and
recipient's serum both fresh as well as stored specimens. The
latter represents serum containing the highest level of cytotoxic
antibodies, determined at the monthly screening. Patients who
had a positive crossmatch with old serum samples did not
undergo transplantation, although the crossmatch results were
negative when tested with the fresh serum.
Harvesting and preservation methods. Approximately one-
half of the kidneys that we transplanted were harvested by our
surgical team and one-half were obtained from other transplant
centers. Most cadaver kidneys were preserved in the hypother-
mic pulsatile perfusion machine for varying lengths of time,
prior to transplantation. Kidneys with poor perfusion character-
istics were not used.
Post-transplant immunosuppressive therapy. The drugs used
for post-transplant immunosuppression have remained the
same in all time periods. However, the following changes have
occurred: (1) there was a progressive reduction in the dose of
intravenous steroids, used initially for prophylactic immuno-
suppression and subsequently for the treatment of rejection
episodes; (2) the maintenance dose of oral prednisone pre-
scribed for long-term immunosuppression was reduced to 15
mg/QOD; (3) antilymphoblast globulin prepared at the Universi-
ty of Minnesota was administered in period 3, instead of the
ALO prepared at Kallstead Laboratories, Chaska, Minnesota,
which was used during the preceeding time periods.
The current protocol for post-transplant immunosuppression
is shown in Figure 2. Azathioprine and steroids were the two
basic drugs used. Intravenous methyiprednisolone sodium sue-
cinate (Solu-Medrol) was administered initially for prophylactic
immunosuppression, at a dose of 1 g/day, which was reduced by
half at 2-day intervals and discontinued on day 7 post-trans-
plant. Oral prednisone was begun during the second week at a
dose of 60 mg/day and gradually reduced to 20 mg/day at 3
months and 15 mg/day at 6 months after transplantation. A year
after transplantation, all patients with stable renal function had
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Table 2. Protocol for conversion of prednisone to alternate day
therapy
Prednisone dose, mg/day
—- —
-
Duration interval
weeksOdd day Even day
15 15 2
20 10 2
25 5 2
30 0 4
25 0 4
20 0 4
15 0
Total duration 4.5 months
the dose of prednisone changed from every day to every other
day, as outlined in Table 2. Antilymphocyte globulin was
administered intravenously at a dose of 15 mg/kg/day during the
initial 2 weeks, except for patients who received HLA identical
sibling donor transplants. Azathioprine dose was reduced from
2.5 to 2.0 mg/kg/day at 3 weeks post-transplant and maintained
at that level unless there was evidence of severe infection,
leucopenia, or liver dysfunction.
Acute cellular rejections were treated with intravenous Solu-
Medrol starting at 1 g/day. The dose was reduced by half at 2-
day intervals and discontinued after 6 days. On day 7 of
antirejection therapy, oral prednisone was begun at 60 mg/day.
The dose was reduced at weekly intervals, 10 mg at a time, until
the prerejection dose was reached. Graft irradiation was used
only in selected instances, totalling 450 rads, given on 3
alternate days. Antilymphocyte globulin was not used for the
treatment of rejection episodes.
Renal biopsies Jbr the diagnosis and managment of rejection
episodes. The diagnosis of rejection was made primarily on
clinical grounds in period 1. However, in the later time periods,
more emphasis was placed on histological confirmation of the
rejection episodes. Only one physician performed the needle
biopsies of renal allografts. All transplant biopsy specimens
were taken in the patient's own room. Only in rare instances
was the patient transferred to the x-ray department and the
biopsy was then done with the guidance of an ultrasound or a
CT scanner. The indications for obtaining the biopsy specimen
were the following: (1) an increase of 25% or more in the mean
serum creatinine level (average of three consecutive measure-
ments) compared to the baseline value, without an adequate
explanation, (2) significant abnormalities in the urine sediment,
(3) nephrotic range proteinuria, (4) unexplained, acute deterio-
ration in renal function, (5) second or subsequent rejection
episodes (even if the patient had the classical clinical signs) and
(6) failure to respond to the conventional antirejection therapy,
in patients whose first rejection episode was diagnosed and
treated on clinical grounds. If the biopsy showed evidence of
acute tubular necrosis (ATN), drug-induced interstitial nephri-
tis, acute vascular rejection, chronic rejection, "denovo" or
recurrent glomerulonephritis, additional immunosuppressive
drugs were not administered.
Acceptance of high risk patients in the later time periods.
After the organizational changes were made, the acceptance
criteria for transplantation were liberalized. This change in
policy is reflected by the increased number of high risk patients
receiving kidney transplants at our institution during the later
time periods (Fig. 3). The number of patients with live donor
transplants decreased from 27% in period I to 5% in period 3,
while the proportion of insulin-dependent diabetic patients
increased from 5 to 21%. The percentage of older patients (50
years and above) had changed from 4 in period I to 31 in period
2, and 28 in period 3. Nine patients received second transplants
in period 1, 17 in period 2, and 15 in period 3. The proportion of
patients with co-existing medical problems increased steadily
during the later time periods. Only 4% of the patients undergo-
ing transplantation in period 1 had pre-existing coronary artery
disease (established angina or myocardial infarction). The num-
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Fig. 3. The proportion of high risk patients receiving renal transplants in different time periods.
Table 3. Clinical characteristics of patients and kidney allografts in the three time periods
Clinical characteristics
Period
1965 to 1
(100)"
I
974
Period 2
1974 to 1977
(100)"
Period 3
1977 to 1980
(100)"
Cadaver TXs 73 84 95
Recipient's mean age at TX, years 34.07 40.66 40.10
Older patients, 50 years and above 4 31 28
Diabetic patients 5 12 21
Patients with multiple TXs 9 17 15
Number of patients with two or more significant
medical problems at TX 5 24 28
Mean number of problems for each patient 0.34 1.02 1.09
Number of patients with Caucasian race 95 91 91
Mean duration of prior dialysis, months 16 19.3 14.5
Number of patients who had pre-TX splenectomy 72 78 99
Number of patients who had pre-TX blood
transfusions 70 85 96
Mean number of units for each patient 17 12.5 12.2
Number of patients with 50% or more cytotoxic
antibodies at TX 8 9 3
Mean value for each patient, % 8.9 9.7 4.5
Number of kidneys with three or more mis-
matched antigens in the AB locus 10 8 5
Mean number of mismatches for each kidney 1.48 1.31 1.42
Mean cold ischemia time for each kidney, hr 14.3 22 26.3
Number of kidneys with post-TX ATN 39 38 42
Number of patients receiving post-TX ALG 82" 46" 83'
Number of allografts functioning for 12 months
and beyond 61d 69' 8ld
Abbreviations: TX, transplant; ATN, acute tubular necrosis; ALG, antilymphocyte globulin.
"The number in parentheses represents the total number of transplants in each separate time period.
ALG was prepared in Kalistead Laboratories.
ALG was prepared at the University of Minnesota Laboratories.
d The figure represents absolute graft survival at 1 year.
ber rose to 7% in period 2 and 10% in period 3. Hypertensive
cardiovascular disease (EKG evidence of left ventricular hyper-
trophy or cardiomegaly by chest x-ray) was present in 3% of the
patients in period 1, 11% in period 2, and 14% in period 3.
Peptic ulcer disease was present in 7, 9, and 11% of patients
transplanted in periods 1, 2, and 3, respectively.
Other policies and procedures. The clinical characteristics of
the patients and the renal allografts in the three time periods are
summarized in Table 3. The number of patients undergoing
pretranspiant splenectomy had increased from 72% in period 1
to 99% in period 3. Pretransplant blood transfusions were
discouraged in period 1. The policy remained neutral in period
2. Presently, all patients receive a minimum of 5 U of packed
cells prior to transplant surgery. Usually 3 U are administered
before splenectomy and 2 at the time of splenectomy. The
policy regarding graft selection remained the same in all pen-
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Table 4. Covariates screened for their association with graft survival
Variable Measurement unit
Patient's age at TX Years
Donor source Live donor/cadaver
Duration of prior dialysis Months
Diabetes Yes/No
Significant medical problems at
TXa Oto7
Pre-TX splenectomy Yes/No
Previous transplants Number of prior TXs
Pretranspiant blood transfusions Number of units
Cytotoxic antibodies at TX Percent
Cold ischemia time Hours
HLA tissue typing: AB mis-
matches Number of antigens mismatched
Post-transplant ATN Yes/No
Prophylactic ALG treatment Yes/No
Time periods
T13b (1 vs. 3) 1 = first period, 0 = otherwise
T231' (2 vs. 3) 1 = second period, 0 = other-
wise
Abbreviations: TX, transplant; ATN, acute tubular necrosis; ALG,
antilymphocyte globulin.
a Seven significant medical problems were considered at the time of
transplantation. These include coronary artery disease, cerebrovascu-
lar accident, hypertensive heart disease, gastrointestinal disorders
(such as peptic ulcer, pancreatitis, and diverticulitis), hepatitis, prior
malignancies, and chronic obstructive pulmonary disease. A value of I
was given for each of the above seven medical problems.
' Theseare two indicator variables used to compare the graft survival
results in three time periods; T13 for period 1 vs. 3 and T23 for period 2
vs. 3.
ods. Only under unusual circumstances would a donor's kidney
with three or more mismatched antigens be chosen for trans-
plantation. More than 80% of patients received prophylactic
ALG during the first and third periods. Only 46% received ALG
in the second period.
Only a small proportion of patients with high levels of
cytotoxic bodies were able to receive kidney transplants at our
institution (8, 9, and 3%, respectively in the three time periods).
More than 90% of patients transplanted in each period belonged
to the Caucasian race. The nonwhite population was equally
distributed among American Indians, blacks, and other immi-
grants. The mean cold ischemia time and the proportion of
kidneys with post-transplant ATN were higher during period 3
compared to other periods.
Less than 5% of the patients who were evaluated for trans-
plantation were rejected on medical or psychiatric grounds.
Presently, anyone receiving chronic dialysis under 70 years of
age is considered a candidate for transplantation, if the patient
has an estimated life span of 2 or more years and has the
potential for improving the quality of life and status of
rehabilitation.
Statistical analysis
The primary objective of our study was to compare the renal
allograft survival among patients transplanted in the three time
periods. Since the patients or allografts were not randomized
during this study period, we used the exploratory multivariate
regression analysis for "censored data" proposed originally by
Cox [16]. The Cox model is an excellent tool to assess the
influence of each variable on the graft survival results, while the
effects of all other variables are fixed. Thus, the model permits
statistical comparison of the grafts transplanted in the three
time periods, while adjusting simultaneously for the differential
distribution of all other factors considered to affect the survival.
X(t) is the hazard function, also called the force of mortality
of the ith graft at time t when values of k covariates or factors
X11, X2, X, are considered; the Cox regression models
were based on the assumption of proportional hazards and
expressed as:
X1(t) = X0(t) exp(p xj= 1
where X0(t) is the hazard function of the underlying graft
survival distribution, when all the covariates are ignored. The f3
regression coefficients can be interpreted as measures by which
the risk would be increased (positive f3) or decreased (negative
/3) in an imaginary experiment where the value of a particular
covariate would be changed while all others remained the same.
To compare the graft survival results in the three time
periods, we used the assumptions based on the Cox proportion-
al hazards model. The three periods were represented by two
indicator variables T13 and T23 to compare the last period with
that of the first and second periods. (T13: 1 = if transplanted in
the first period and 0 = otherwise; T23: 1 = if transplanted in the
second period and 0 = otherwise.) The comparison between the
first and second period (T12) was based on (/313 — /323) in which
the variance of this estimated coefficient was obtained using the
method of error propagation, that is,
Var (/ — 1323) = Var () + Var (/23) — 2 Coy (1i, p23).
In addition to the time periods, we screened the following 13
variables for their association with the graft survival (Table 4).
They were (1) recipient's age at the time of transplantation; (2)
donor source, living related or cadaver; (3) length of prior
dialysis; (4) presence or absence of diabetes; (5) co-existing
medical problems; (6) pre-transplant splenectomy; (7) number
of previous transplants; (8) pre-transplant blood transfusions;
(9) percent cytotoxic antibodies at the time of transplantation;
(10) cold ischemia time; (11) mismatched antigens in the HLA-
A and HLA-B loci; (12) post-transplant ATN; and (13) treat-
ment with ALG.
As our computer program was written to allow for only 15
covariates, the seven pre-existing medical conditions (coronary
artery disease, cerebrovascular accident, hypertensive heart
disease, gastrointestinal disease, hepatitis, prior malignancy,
and chronic obstructive pulmonary disease) were initially com-
bined into a single variable and called the number of significant
medical problems at the time of transplantation. This variable
had a value which ranged from 0 to 7. We felt that if this
combined factor turned out to be significant, a second analysis
should be done to separate the effects of the individual variables
in this subgroup. But, the combined factor was not significant,
therefore, a second round of analysis was not done.
To fit the Cox regression models, we used the FORTRAN
program published by Kalbfleisch and Prentice [17], with minor
modifications. The estimated p coefficients were obtained and
the approximate two-sided significance (P value) of each stan-
dardized coefficient was assessed with reference to normal
distribution. When a coefficient was significant at the 5% level
(P < 0.05), the relative risk or benefit for the corresponding
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Table 5. Primary event leading to graft loss in the three time periods in the follow-up yearsa
Time periods (1) Time periods (2) Time periods (3) Time periods
Cause of graft loss 1 2 3 1 2 3 I 2 3 1 2
(4)
3
Time
1
periods (5)
2 3
Patient death from all causes 16 6 13 6 4 1 0 5 1 1 0 0 4 1 0
Irreversible graft rejection 23 25 6 5 3 1 2 I 1 2 0 0 1 0 0
TOTAL 39 31 19 ii 7 2 2 6 2 3 0 0 5 / 0
a The follow-up year is placed in parentheses after each time period heading.
Table 6. Survival analysis with covariate adjustment for all 300 renal allografts
Co-variate Coefficient SE Normal deviation P value
Age at TXa 0.18810 0.009455 1.989495 0.0466
Donor source
—0.007555 0.296590
—0.025473 0.9797
Prior dialysis 0.000138 0.000196 0.704781 0.4809
Diabetesa 0.931627 0.286947 3.246691 0.0012
Other medical problems 0.109689 0.109111 1.005293 0.3148
Splenectomy —0.312724 0.214921 —1.455063 0.1457
Previous transplants 0.246012 0.256788 0.958035 0.3380
Blood transfusions
—0.006970 0.006405
—1.088197 0.2765
Cytotoxic antibodies 0.007407 0.004478 1.654144 0.0981
Cold ischemia time 0.013590 0.009240 1.470814 0. 1413
Antigen mismatchesa 0.236635 0.95343 2.481944 0.0131
Post-TX ATN 0.391702 0.212640 1.842091 0.0655
ALG treatmenta —0.846272 0.223787
—3.781588 0.0002
Time periods'
T12b(1 vs. 2) 1.175003 0.443495 2.649416 0.0080
T13 (1 vs. 3) 1.631087 0.319642 5.102852 <0.0001
T23 (2 vs. 3) 0.456084 0.296188 1.539846 0.1236
a This factor proved to be statistically significant influencing graft survival at the 5% level.
' The result for this variable was calculated separately using those of T13 and T23. T is the indicator variable used to compare period i versus pe-
nod j.
factor was calculated from the estimated /3 coefficient, that is, r
= e/3. The length of survival was measured as the time elapsed
in months from the day of transplantation until the day of graft
failure (either due to patient's death or other causes) and
"censored" for those grafts still functioning on the day when
the data was collected for statistical analysis, that is, May 6,
1981. Using fitted results of the Cox models, survival curves
were then plotted for different subsets of patients showing the
influence of some important variables on the graft survival
results.
Results
Of the 300 consecutive patients included in this study, 169
were men and 131 were women. Forty-eight (16%) received live
donor transplants and 252 (84%) received cadaver kidneys. The
mean age for the entire group was 38.3 years (range, 15 to 69
years). Glomerulonephritis was the primary disease in 123
patients (41%). Thirty-eight (12.7%) had diabetic nephropathy
and 23 (7.7%) had hypertensive nephrosclerosis.
Cumulative graft survival results. The absolute graft survival
rate at 1 year (actual number of transplants functioning for a
year or more) was 61% in period 1, 69% in period 2, and 81% in
period 3. The primary event leading to graft loss in the three
time periods is shown in Table 5. The graft loss at 1 year has
gradually decreased from 39% in period Ito 19% in period 3. It
is pertinent to note that most of the kidney loss in period 3 was
related to patient's death with a functioning transplant, rather
than graft rejection.
Signf1cant factors influencing graft survival results. Of the
15 co-variates screened for their association with the graft
survival, only five had a significant positive or negative effect
(these are indicated by footnote a at the beginning of the
variable in Table 6). The /3 regression coefficient, the SE, normal
deviation, and the statistical significance (P value) of each of
these 15 variables are also shown in Table 6. Advanced age,
diabetes, and antigenic mismatches had a significant negative
effect, but the ALG treatment and time periods exerted a
significant positive effect on the graft survival results (P <
0.05). The effect of another variable post-transplant ATN was
near the borderline (P = 0.06). Live donor transplantation, pre-
transplant blood transfusions, and splenectomy had a slightly
favorable effect, but this was not statistically significant. The
percent cytotoxic antibodies, coexisting medical problems,
previous transplants, length of prior dialysis, and cold ischemia
time had an unfavorable effect but were also shown not to have
any significant influence on the survival of renal transplants.
Effect of time periods. The graft survival results between the
time periods were compared, adjusting simultaneously for the
differential distribution of all the other 13 factors. The kidneys
transplanted in the second period had better survival than those
transplanted in the first period (P = 0.008). The improvement in
the graft survival rate during the third period was highly
significant when compared to the first period (P < 0.0001).
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Table 7. Ratio of relative risk for significant factors
Variable Relative risk ratio
Prognostic variables
AgeatTXa 1.019
Diabetes 2.539
Antigen mismatchesb 1.267
ALG treatment 0.447
Time periods
1 versus 2 3.240
1 versus 3 5.109
a The risk increased for each additional year.
b The risk increased for each additional mismatch.
When the results were compared between the second and third
periods, observed data indicated improved graft survival rate in
the third period, but this was not statistically significant (P =
0.12).
Relative risk ratio for significant factors. For those factors
which had a significant influence on the allograft survival, the
ratio of relative risk or benefit was calculated and the results are
shown in Table 7. For each additional year of age at the time of
transplantation, the risk for graft survival increased by a ratio of
1:1 019. For each additional mismatch in the AB locus, the risk
increased by a ratio of 1:1 267. This ratio implies that shifting
of the mismatches from a lower grade to a higher grade would
result in a 26% increase in the risk function value, if all the other
screened variables remained constant in a hypothetical trans-
plant population. The presence of diabetes increased the risk
2.5 times, while receiving prophylactic ALG reduced the risk
approximately 50%. The risk of receiving a kidney transplant
during period I was three times higher compared to period 2 and
five times higher compared to period 3.
Effect of diabetes and prophylactic ALG in different rime
periods. The graft survival results during the three time periods
are shown graphically for both diabetic and nondiabetic pa-
tients, with and without the ALG treatment (Figs. 4 and 5).
These figures were constructed for a typical patient in our
transplant program using the fitted results of Cox models in
which all other covariates were fixed at the average values. The
renal allografts of diabetic patients, who did not receive ALG in
period 1, had the worst prognosis (Fig. 4A). The graft survival
rate at 1 year was 4.7% and at 5 years 0.4%. The I and 5 year
graft survival results improved to 26 and 9%, respectively,
when they received prophylactic ALG (Fig. 4B). The renal
transplants of nondiabetic patients, who received prophylactic
ALG in period 3, had the best chance to survive. The graft
survival rate at 1 year was 90.4% and at 5 years was 83.1% (Fig.
SB). In the same group of patients, when they did not receive
ALG, the graft survival rate decreased to 79% at 1 year and 65%
at 5 years (Fig. 5A). In every category of patients studied, the
graft survival results in period 3 were better compared to other
time periods.
Effect of HLA matching. The effect of HLA-A and HLA-B
antigenic mismatches on the graft survival results was studied
in the subgroup of nondiabetic patients who received prophy-
lactic ALG in period 3. These results are shown in Table 8. In
this group of patients if all the four antigens were mismatched,
the graft survival rate at 1 year was 83% and at 5 years 71%.
When there were no antigenic mismatches between the donor
Table 8. Effect of HLA matching on the renal allograft survival
(nondiabetic patients receiving ALG in period 3)
.Mismatched antigens
in the AB locus
Proportion of functioning allografts
1 year 2 years 5 years
0 0.930 0.906 0.876
1 0.912 0.882 0.845
2 0.890 0.853 0.808
3 0.863 0.817 0.763
4 0.830 0.775 0.710
and the recipient, the graft survival rate improved to 93% at I
year and 87% at 5 years.
Discussion
The most dramatic change in renal transplantation in recent
years has been the improvement in patient survival rate. In
1974, the 1 year patient survival in recipients of primary
cadaver renal allografts was 72.3% [18]. The recent survey by
the Standards Committee of the American Society of Trans-
plant Surgeons [191 indicated that the survival rate of these
patients at 1 year has increased to 88.6%. A similar increase in
patient survival was reported by the European dialysis and
transplant registry [20], Australian and New Zealand dialysis
and transplant registry [21], and some individual transplant
centers [14, 15] in the United States. The marked improvement
in patient survival was primarily attributed to the avoidance of
high dose immunosuppressive drugs during the post-transplant
period. Despite the improvement in patient survival statistics
across the world, the graft survival results in cadaveric trans-
plant recipients remained low. The 1 year actuarial graft surviv-
al rate ranged from 51 to 58% in different reports [14, 15, 19, 20,
21].
At our institution, we adapted a similar policy and gradually
decreased the dose of intravenous steroids used initially for
prophylactic immunosuppression and subsequently for the
treatment of acute rejection episodes. We also observed an
improvement in the patient survival rate although the data has
not been presented in this report. In addition, our analysis
indicated a gradual but continuous improvement in graft surviv-
al results among recipients of cadaveric renal transplants during
the past 15 years. Despite the acceptance of high risk patients in
the later time periods, the actual number of kidney allografts
functioning for a year or more has increased from 61% in period
I to 69% in period 2, and 81% in period 3. Since most
transplants performed in periods 2 (84%) and 3 (95%) were of
cadaveric origin, these results clearly signify the improved
survival of cadaveric renal transplants at our institution.
The question that comes to everyone's mind is "what caused
this improvement?" In a complex clinical setting such as kidney
transplantation, it is virtually impossible to attribute the success
or failure to any given factor. Many factors may be exerting
their influence simultaneously to affect the ultimate outcome.
However, with the aid of modern statistical methods [16, 22, 23]
one can attempt to study the significance of each one from a
group of selected factors known to affect the survival results.
Such models would also permit statistical comparison of the
results obtained in different time periods by making the grafts
comparable on all other factors on which the data are available.
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In this study we used the Cox model to evaluate the significance
of the time periods on the graft survival results, while the effects
of 13 other variables were held constant. These statistical
methods cannot substitute for the ideal medical experiment in
which the patients and allografts are randomized to a control
and experimental group, thus giving the best assurance of
comparability among these groups for factors affecting the
survival. Since the patients or allografts were not randomized
during this study period, we had to utilize the available meth-
ods, while recognizing the limitations of our inferences.
In this analysis, we focused our attention primarily on the
renal allograft survival and compared the clinical results be-
tween the three time periods, We also screened the following 13
variables for their association with the graft survival: (1)
recipient's age, (2) donor source, (3) length of prior dialysis, (4)
presence of diabetes, (5) co-existing medical problems, (6)
splenectomy, (7) previous transplants, (8) blood transfusions,
(9) percent cytotoxic antibodies, (10) cold ischemia time, (11)
HLA-mismatches, (12) post-transplant ATN, and (13) prophy-
lactic ALG treatment. These variables were selected on the
basis of published reports and our own clinical observations.
The analysis of our data indicated that (I) the graft survival
results were significantly better during the second and third
periods, compared to the first period, and (2) in each time
period, advanced age, diabetes, and HLA mismatches exerted a
significant negative effect, while the prophylactic ALG was
beneficial for the survival of renal allografts.
Effect of age. Although the association between the recipi-
ent's age and graft functional survival seems natural, the
interpretation could be misleading. It is important to note that
currently available statistical methods such as the Cox model
assume a linear relationship between the survival time and each
Fig. 4. The influence of prophylactic ALG on
the renal allograft survival among diabetic
patients transplanted in periods 1, 2, and 3. A
Without ALG. B With ALG.
covariate. However, the clinical observations [241 indicate that
the recipient's age and graft survival have a tub-shaped relation-
ship with the middle-aged patients doing significantly better
than the very young and the very old.
Effect of diabetes. Our observation that diabetic patients
have a lower graft survival rate agrees with other reports [18,
24] published earlier in the literature. The possible causes
include (1) inability of the diabetic patient to withstand aggres-
sive antirejection therapy, (2) the tendency of physicians to stop
the immunosuppressive drugs early when diabetic patients
develop an infectious complication, (3) progressive vascular
disease leading to death from myocardial infarction, cerebro-
vascular accident, or congestive heart failure, (4) local factors
such as wound infection, bladder, or ureteral leaks, throm-
boembolic events in the renal vessels, or other technical
problems.
Effect of HLA-matching. Despite some earlier controversies
[25] regarding the practical benefit of HLA matching in renal
transplantation, recent reports [24, 26—28] clearly indicate that
HLA matching has an important prognostic value. Our analysis
showed that each additional mismatch in the AB locus in-
creased the risk by a ratio of 1 to 1.3. The graft survival rate
decreased progressively when the antigenic disparity between
the donor and recipient increased. The HLA matching seemed
to exert its beneficial effect even 5 years after transplantation.
Persijn et al [28] from the Eurotransplant Foundation reported a
significant improvement in patient and graft survival results in
recipients of well matched kidneys (51% graft survival at 5
years), compared to those who received poorly matched kidney
allografts (31% graft survival at 5 years). They analyzed 2522
first cadaver renal transplants to establish the effect of HLA
matching on the renal allograft survival.
1 2 3 4 5 1 2 3 4
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Fig. 5. The effect of prophylactic ALG on
graft survival rate among nondiabetic patients
transplanted in periods 1, 2, and 3. A Without
ALG. B With ALG.
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Effect of ALG treatment. The use of prophylactic ALG had a
significant positive effect on the survival of renal allografts in
both our diabetic and nondiabetic patients. Irrespective of the
type of preparation (whether from the University of Minnesota
or from Kallstead Laboratories) the dose or the duration of
ALG therapy seemed to exert its beneficial effect, uniformly in
all time periods. For instance, during period 2 approximately
half of the patients received ALG. In this period, the use of
ALG resulted in a 16% improvement in the 1 year graft survival
rate among nondiabetic patients and 27% in the diabetic pa-
tients. Sheil et al [29], Launois et al [301, and Kreis et al [131
reported similar improvement in graft survival results following
the use of prophylactic ALG in controlled clinical experiments.
Effect of time periods. The improvement in graft survival
results observed during periods 2 and 3 was independent of the
effects of the 13 variables that we screened. It is possible that
other unknown factors may have had a significant influence.
The improved methods of tissue typing and crossmatching may
have reduced the incidence of early graft loss from hyperacute
and accelerated acute rejections, by allowing better selection of
the renal allografts prior to transplantation. However, we
believe that the primary patient care provided in an academic
environment played an important role in minimizing the rate of
graft loss in our transplant recipients.
Comprehensive patient care in an academic environment. At
Hennepin County Medical Center, we have an integrated
dialysis and transplant program. When patients present with
endstage renal failure, decisions are made early whether the
patient could be a transplant candidate or will remain on
chronic dialysis. Irrespective of the place where they dialyze,
all potential transplant recipients were evaluated by the medical
team using our standard clinical protocols. After transpianta-
tion, patients received their "total care" provided under the
guidance or direct supervision of the three staff physicians.
Therefore, the principles of management were fairly consistent
during the later time periods. This sort of approach enabled us
to detect many of the medical, surgical, and psychosocial
problems early, which may have an important bearing on the
patient's health overall and graft function in particular.
The consorted efforts of the medical, surgical, and paramedi-
cal support personnel helped us achieve the best possible
patient cooperation with our treatment program. As a result,
the voluntary discontinuation of immunosuppressive drugs and
subsequent graft loss was avoided. Zoller et al [31] reported that
21(44%) of the 48 patients who discontinued their immunosup-
pressive drugs had subsequent graft loss within a mean period
of 5 months.
Allograft biopsies. The frequent use of allograft biopsy
specimens in the management of patients with reduced renal
function aided us in tailoring the immunosuppressive therapy to
the existing needs. When biopsy specimens showed evidence of
ATN, allergic interstitial nephritis, transplant glomerulopathy,
recurrent or "denovo" glomerulonephritis, or chronic vascular
rejection, additional immunosuppressive drugs were withheld.
Avoidance of such unnecessary antirejection therapy and the
policy of reducing the dose of corticosteroids helped us lower
the death rate from both infectious and thromboembolic compli-
cations [32]. Thereby, the incidence of graft loss due to patient
death was reduced. Finkeistein et al [33], Brown et al [34],
Banfi et al [351, and Richardson et al [361 have previously
documented the usefulness of transplant biopsies in the man-
agement of patients with reduced renal function.
Our results cannot be compared to the results obtained at
other centers, since the clinical characteristics, acceptance
1 2 3 4 5 1 2 3 4 5
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criteria, and philosophies in patient care differ considerably
between the transplant programs. For example, at many institu-
tions the "transplant biopsy" is considered a dangerous inva-
sive procedure, and the physicians rely on other nonspecific
tests for the diagnosis and management of rejection episodes.
We do not mean to underscore the serious complications which
could potentially occur after a blind needle biopsy. The decision
obviously has to be made based on the clinical situation and the
local experience. In a series of 200 allograft biopsies at our
institution, the complication rate was minimal. Only ten pa-
tients (5%) had transient gross hematuria, but none of them
required blood replacement or surgical intervention. Because of
inadequate tissue sample, the biopsy had to be repeated in 20
patients (10%) using the facilities of an ultrasound or a CT
scanner.
In the kidney transplant histocompatability study Barnes and
Oliver [37] analyzed a number of factors for their association
with graft survival, using similar statistical methods. The data
for this study was provided prospectively by a number of
transplant centers. When the graft survival results were com-
pared between 20 large transplant units after allowing for the
effects of important variables, a significant "center effect" was
discovered, which could not be explained by chance alone.
There was a three-fold difference in the graft survival rate
between the center with the worst results and the center which
had the best results. Such "center effect" was also demonstrat-
ed in other studies [38, 39] after due allowance was given to the
major variables. Unfortunately in all these studies, the follow-
up care the patients received could not be quantitated like the
other variables (splenectomy, HLA match, and so forth).
Based on our experience, we would recommend cadaveric
transplantation for all eligible patients who have no suitable
family donors. The improved life style, excellent rehabilitation,
and reduction in long-term costs are some of the other consider-
ations in choosing this form of therapy for patients with
endstage renal failure.
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